Dermatology Research
Moderate to Severe Atopic Dermatitis Study
Controlled Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients with Moderate-to-Severe Atopic Dermatitis
AGE: 18-55 years old
SEX AT BIRTH: All
SEX AT BIRTH: All
TYPE: Investigational Treatment Study
CONDITION: Atopic Dermatitis (Eczema)
CONDITION: Atopic Dermatitis (Eczema)
HEALTHY PARTICIPANTS: No
LOCATION: UH Cleveland Medical Center
LOCATION: UH Cleveland Medical Center
Learn More About This Research Study
For more information, please contact study coordinator, Dr. Emma Larson at at 216-844-5278 or by completing the form below.
Study Purpose
The purpose of this study is to evaluate the impact of lebrikizumab on vaccine responses (TDaP and meningococcal) in patients with moderate-to-severe Atopic Dermatitis. This study will further assess the efficacy and safety of lebrikizumab in patients with AD.
Who Can Participate
Participants between 18-55 years old with moderate to severe atopic dermatitis (eczema) and have not had a TDaP or meningococcal vaccines in the last 5 years may be eligible for this study.
STUDY ID#
- STUDY20201892